首页> 外国专利> New quinazoline compounds are tyrosin-kinase inhibitors e.g. to treat cancer, hematologic or solid tumors, non-Hodgkin tumors or T-cell lymphoma; and for the modulation of the cell cycle, cell differentiation, apoptosis or angiogenesis

New quinazoline compounds are tyrosin-kinase inhibitors e.g. to treat cancer, hematologic or solid tumors, non-Hodgkin tumors or T-cell lymphoma; and for the modulation of the cell cycle, cell differentiation, apoptosis or angiogenesis

机译:新的喹唑啉化合物是酪氨酸激酶抑制剂,例如。治疗癌症,血液学或实体瘤,非霍奇金瘤或T细胞淋巴瘤;并用于调节细胞周期,细胞分化,凋亡或血管生成

摘要

Quinazoline compounds (I) and their salts with counter ions are new. Quinazoline compounds of formula (I) and their salts with counter ions are new. R 1, R 2H, OH, halo, CN, NO 2, one or more times saturated 1-10C-alkyl (which is optionally 1-3 times substituted by OH, halo or 1-5C-alkoxy, and interrupted by one or more O, S, N, carbonyl or sulfonyl group, aliphatic or aromatic 5-7 membered homo or heterocyclic ring system), one or more times saturated 1-10C-alkoxy (which is optionally 1-3 times substituted by OH, halo or 1-5C-alkoxy, and interrupted by one or more O, S, N, carbonyl or sulfonyl group, aliphatic or aromatic 5-7 membered homo or heterocyclic ring system), one or more times saturated 1-10C-alkylthio (which is optionally 1-3 times substituted by OH, halo or 1-5C-alkoxy, and interrupted by one or more O, S, N, carbonyl or sulfonyl group, aliphatic or aromatic 5-7 membered homo or heterocyclic ring system), or 1-5C-perfluoroalkyl (optionally one or more times unsaturated); R 3, R 4H, halo, CN, NO 2, CF 3or 1-4C-alkyl; R 5an aliphatic or aromatic 5-7 membered homo- or heterocyclic ring system, which can be condensed with 1 or 2 further aliphatic or aromatic 5-7 membered homo- or heterocyclic ring systems, which is optionally substituted by halo, CN or NO 2, or 1-4C-alkyl or 1-4C-alkoxyl, 2-4C-alkenyl, 2-4C-alkynyl (all optionally one or more times saturated and substituted by phenyl or halogenated phenyl group); L : N(R 6), O, C(=O)-, -O-C(=O)- or -C(=O)-O-, -N(R 6)-C(=O)- or -C(=O)-N(R 6)-, -N(R 6)-O- or -N(R 6)-O-, -O-N(R 6)-C(=O)- or -C(=O)-N(R 6)-O-, -N(R 6)-C(=O)-O- or -O-C(=O)-N(R 6)-; and R 6H or 1-4C-alkyl. Provided that: at least one residue of R 1or R 2is not H. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Cytostatic; Angiogenesis Modulator; Antiinflammatory; Antiasthmatic; Antiallergic; Ophthalmological; Dermatological; Antiarthritic; Osteopathic; Antirheumatic; Gastrointestinal-Gen.; Antibacterial; Immunosuppressive; Antidiabetic; Hemostatic; Neuroprotective; Muscular-Gen.; Antipsoriatic; Nephrotropic; Respiratory-Gen.; Anabolic; Anorectic; Cardiant; Antiapoptotic. MECHANISM OF ACTION : Tyrosin-kinase inhibitor.
机译:喹唑啉化合物(I)及其与抗衡离子的盐是新的。式(I)的喹唑啉化合物及其与抗衡离子的盐是新的。 R 1>,R 2> H,OH,卤素,CN,NO 2一次或多次饱和的1-10C-烷基(可被OH,卤素或1-5C烷氧基取代1-3次,并被间断通过一个或多个O,S,N,羰基或磺酰基,脂族或芳族5-7元均杂环或杂环系统),一个或多个饱和1-10C-烷氧基(可选被1-3 OH取代) ,卤素或1-5C-烷氧基,并被一个或多个O,S,N,羰基或磺酰基,脂族或芳族5-7元均杂环或杂环系统打断),1或多次饱和1-10C-烷硫基(其任选地被OH,卤素或1-5C-烷氧基取代1-3次,并被一个或多个O,S,N,羰基或磺酰基,脂族或芳族5-7元均杂环或杂环系统打断)或1-5C-全氟烷基(可选不饱和的1或多次); R 3>,R 4> H,卤素,CN,NO 2,CF 3或1-4C-烷基; R 5>脂族或芳族5-7元均杂环或杂环体系,其可与1或2个另外的脂族或芳族5-7元均杂环或杂环体系稠合,其任选地被卤素,CN或C 1取代。 NO 2或1-4C-烷基或1-4C-烷氧基,2-4C-烯基,2-4C-炔基(全部任选地被苯基或卤代苯基饱和并取代一次或多次); L:N(R 6>),O,C(= O)-,-OC(= O)-或-C(= O)-O-,-N(R 6>)-C(= O)-或-C(= O)-N(R 6>)-,-N(R 6>)-O-或-N(R 6>)-O-,-ON(R 6>)-C(= O )-或-C(= O)-N(R 6>)-O-,-N(R 6>)-C(= O)-O-或-OC(= O)-N(R 6>) -; R 6> H或1-4C-烷基。前提是:R 1>或R 2>的至少一个残基不是H。包括独立的权利要求用于制备(I)。 [图像]活动:细胞抑制作用;血管生成调节剂;消炎(药;抗哮喘抗过敏;眼科皮肤;抗关节炎整骨;抗风湿;胃肠源抗菌;免疫抑制抗糖尿病止血药具有神经保护作用;肌肉型;对牛皮癣;嗜肾呼吸器;合成代谢厌食的;卡迪恩抗凋亡。作用机理:酪氨酸激酶抑制剂。

著录项

  • 公开/公告号DE102008012435A1

    专利类型

  • 公开/公告日2009-09-03

    原文格式PDF

  • 申请/专利权人 SCHEBO BIOTECH AG;

    申请/专利号DE20081012435

  • 发明设计人 SCHEEFERS HANS;

    申请日2008-02-29

  • 分类号C07D239/72;A61K31/517;

  • 国家 DE

  • 入库时间 2022-08-21 19:09:13

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号